Olympus Latin America: Public Bids and Services Never Performed

In the Olympus Latin America FCPA case, the Justice Department reported nearly $3 million in payments to practitioners that produced more than $7.5 million in profits. Under its deferred prosecution agreement, the company admitted bribing publicly employed healthcare professionals to win medical equipment business through cash, travel and equipment benefits. For someone inside sales or finance, the telling detail is what the paperwork called the payment: in Mexico, administrative and advisory services for public bids that were neither performed nor needed.

The Justice Department announced the Latin America resolution on March 1, 2016, alongside separate domestic proceedings against Olympus Corporation of the Americas. This foreign bribery case followed the business behind the benefits. Buying influence was a profitable sales strategy.

What Conduct Can Violate the FCPA?

The Olympus criminal case under the Foreign Corrupt Practices Act concerned payments and benefits used to influence publicly employed health care professionals to obtain or retain equipment business. The criminal complaint charged that the company used cash, transfers, personal travel and free or heavily discounted equipment for practitioners’ personal use in exchange for purchases. It also alleged that distributors delivered benefits to influence public hospital tender boards, the committees involved in choosing a supplier.

Olympus Latin America distributed medical imaging equipment from Miami to customers in the Caribbean, Central America and South America. The complaint describes a business selling directly to government and private customers and through contracted distributors. Its Brazilian subsidiary, Olympus Optical do Brasil, also sold directly and through distributors, under the Latin America company’s management. A hospital sale could therefore involve the regional company, a local subsidiary and an outside distributor, each with part of the transaction in its records.

The purchasing influence matters as much as the recipient’s job title. In remarks on pharmaceutical industry controls in 2015, the Securities and Exchange Commission’s enforcement director explained that doctors, pharmacists and administrators at public hospitals often decide what their institutions buy and can qualify as foreign officials. Olympus’s complaint made that connection concrete: the alleged benefits targeted practitioners employed by public institutions or sitting on public tender boards. The company was selling equipment to an institution while rewarding people who could steer its choice.

Olympus Latin America Medical Device Payments and the FCPA

The company’s deferred prosecution agreement and statement of facts describe different routes to procurement influence: Mexican agent services, a Brazilian equipment-purchase advance, an off-contract benefit in Bolivia and payments to retain Colombian hospital business. The criminal complaint also named Argentina and Costa Rica among the countries where officials were offered or received improper benefits.

Mexico’s Public-Bid Services Were Never Performed

Under its deferred prosecution agreement, Olympus Latin America admitted that agent payments in Mexico were recorded as administrative and advisory services for public bids even though those services were neither rendered nor required. The entry supplied a commercial explanation for money leaving the company. The work supposedly supporting it did not exist.

We see a particularly pointed version of paperwork hiding a payment here. The claimed service was helping with a public bid, the very purchasing process the payment scheme sought to influence. For a finance or accounting employee, the useful comparison is the recorded service against what the agent actually delivered.

Brazil’s Equipment Business Came With Tender Influence

The criminal complaint alleged payments intended to obtain an endoscopy equipment tender at a public hospital and confidential tender information about a key competitor. It put those payments at approximately $110,000, for the benefit of two publicly employed healthcare professionals.

The complaint also described an email from a Miami employee developing a plan to provide improper benefits to a physician on a Brazilian hospital’s endoscopy tender committee. It alleged subsequent payments benefiting physicians who served on that committee. The procurement advantage therefore reached into the people and information behind the hospital’s decision.

For a competing equipment supplier, confidential information about its bid is part of what makes this conduct consequential. For an insider, the connection lies between the proposed benefit, the physician’s committee role and the pending equipment purchase. We connect those communications with the purchase file and payment approval to understand the transaction.

Bolivia’s Public Purchase and Private Benefit

The criminal complaint alleged that a Miami employee described a Bolivian hospital purchasing an Olympus enteroscope through competitive bidding in exchange for a donation of an endoscopy tower and accessories to a physician’s private clinic. The equipment was for the physician’s personal use. A public hospital’s purchase was tied to a benefit delivered elsewhere.

Under its deferred prosecution agreement, Olympus Latin America also admitted an off-contract benefit in Bolivia. That makes the formal purchase agreement only part of the story. We put the hospital order and the private benefit side by side, with what employees said connected them. Calling the hospital’s process competitive bidding did not change the exchange alleged in the employee’s email.

Colombia’s Benefits Were About Keeping Business

Under its deferred prosecution agreement, Olympus Latin America also admitted benefits intended to retain a Colombian public hospital’s business. Keeping an account was part of the scheme alongside obtaining new equipment orders. For a sales employee, the telling detail may be why a personal benefit continued after the first purchase.

Training Centers With a Sales Condition

The Justice Department’s announcement described training centers as the principal way Olympus Latin America delivered illicit benefits during the scheme, which ran from 2006 until August 2011. The centers were nominally intended to educate and train doctors but supplied benefits to selected practitioners.

The criminal complaint alleged that Olympus identified influential practitioners as key opinion leaders and routinely provided personal benefits to influence equipment purchases or use. It described a travel program for personal trips and false contracts that concealed benefits. The alleged sales condition was explicit: if a practitioner failed to purchase equipment as agreed, sales personnel were to raise the issue and stop the personal benefits. We see the sales bargain behind the educational label: no purchase, no perks.

The complaint quoted a February 2010 email from a Miami employee sending a revised physician agreement that removed clauses, including the provision about the travel program. The employee’s explanation, translated in the complaint, was blunt:

We see the distinction the employee was drawing: the benefits would remain available while the written agreement would omit them. The allegation concerns a deliberate difference between the deal and the document. For an insider who knows both, that difference can be the most important part of the account.

The Purchase, the Benefit, and the False Record

The useful whistleblower evidence connects the purchasing decision to the benefit and the description used to approve or record it. Olympus’s admissions and the criminal complaint supply concrete examples of those connections: a service with no work behind it, a private equipment benefit tied to a public order, and an email preserving a promise while removing it from the contract.

We connect the customer bargain that sales and distributor employees know with the payment trail finance sees. The person who approved the description and the person who understood the customer bargain may sit in different parts of the business.

The Securities and Exchange Commission’s enforcement director identified another industry pattern in the pharmaceutical speech: distributor margins can fund bribes to officials. He explained that the added layer of cash flow can leave companies recording bribes as apparently ordinary expenses.

The Same Service Fiction in Healthcare Procurement

Fresenius Medical Care provides a close comparison. In its administrative order, the Securities and Exchange Commission alleged payments by Fresenius’s Angolan business to a distributor owned by an official’s sons for storage services that were never performed. The order said the company already had another warehouse lease for the same services. The alleged service fiction resembles the Mexican Olympus payments: a business description without the work.

The order also alleged that Fresenius helped shape a Spanish public hospital tender by supplying a doctor with draft specifications and scoring. The doctor agreed to some proposals through personal email, and Fresenius won, according to the order.

The 2022 Journal of Forensic and Investigative Accounting study Fresenius Medical Care: A Case Study on the FCPA traces how sham consulting, third-party payments and unsupported accounting entries worked together in healthcare sales. It describes tender information obtained through consulting arrangements, gifts, travel and donations. Read together, those categories tell a purchasing story that separate expense accounts can obscure. That is why we connect what the customer was deciding with what the company was promising.

The Separate Domestic Civil Settlement

Olympus Corporation of the Americas agreed to a $310.8 million civil settlement over allegations that kickbacks caused false claims to Medicare, Medicaid and TRICARE. The Justice Department’s announcement identified a former chief compliance officer as the whistleblower who brought that domestic case and said he would receive $7 million from the state share of the settlement. The civil claims concerned federal healthcare payments, while the Latin America criminal case concerned benefits used to influence foreign hospital business.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Foreign bribery information can also qualify for a whistleblower reward, and we help you build the case for the program that fits your information.

You Know What the Payment Was Buying

If you saw an agent paid for work never done or a hospital deal tied to a private benefit, you know the bargain behind the paperwork. Speak with our whistleblower experts about what the payment was buying. We work with you to build the case around the commercial facts, bring in FCPA whistleblower lawyers who understand medical-device sales and public procurement, and stay beside you through the process.